Founded in 2020 by Dr. John Zhu, Duality Biologics is a clinical-stage company based in Shanghai, China. With a focus on oncology and autoimmune diseases, the company has built a pipeline of nearly 10 Best-in-Class and First-in-Class bispecific antibody and Antibody-Drug Conjugate (ADC) drugs. They have also established a next-generation ADC platform with global intellectual property rights. Backed by well-known investors and with $110 million in funding, Duality Biologics aims to address unmet medical needs through their innovative drug development efforts.